Julia Coronella, Ph.D. joined Tanabe Research Laboratories USA in February 2013, and has over 20 years of industrial and academic experience in biological therapy for oncology and other indications. Before joining TRL, she worked in oncology biologics discovery research at CovX, a San Diego biotechnology company involved in engineered antibodies and peptides, which was acquired by Pfizer in 2007. At Pfizer, she led cross-functional teams for the discovery and validation of novel antibody, antibody drug conjugates and peptide-based drugs for oncology. Prior to this, she was at Biogen Idec, where she led a team for antibody discovery in breast cancer and cancer stem cells. Before entering the biotechnology industry, she was research Assistant Professor at the Arizona Cancer Center at the University of Arizona, where she led a research program investigating antibodies produced by breast cancer-infiltrating B cells. She completed her postdoctoral studies at Harvard Institutes of Medicine at Harvard Medical School, and the Arizona Cancer Center at the University of Arizona, and received her Ph.D. in Biology from the University of South Florida.